- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02802553
Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions
Evaluation of an Integrated Imaging System (Smart Goggles) For In Vivo Detection of Fluorescently Labeled Lymph Nodes for Breast Cancer: A Pilot Study To Visualize Sentinel Lymph Nodes After Periareolar Injection of Indocyanine Green
Study Overview
Status
Conditions
Detailed Description
Primary Objective -Positive fluorescence signal in SLNs imaged by the Smart Goggles system.
Secondary Objectives
- Confirmation of ICG within lesions per histologic tissue exam by SLN biopsy.
- Comparison of lesions detected by the Smart Goggles vs. lesions detected using SPY/Quest/PDE vs. gold standard of gamma probe and blue dyes.
Exploratory Objectives
-Collection of preliminary data for a future, powered study for lymphatic mapping in breast cancer
Study Design This is an unpowered pilot study to determine the sensitivity of the new Smart Goggles device, for detection of ICG fluorescence in SLNs of breast cancers in a clinical setting. The investigators have chosen to examine ICG as the contrast agent and breast cancer as the clinical target, because this agent is FDA-approved and is regularly used for lymphatic mapping (skin cancers). The study team will be applying ICG for the same length of time as the standard-of-care procedures including radiotracers and blue dyes. The study involves a single visit, lasting ~3-4 hours total. Multiple SLN biopsies will be performed if multiple SLNs are identified.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stephanie A Valente, DO
- Phone Number: 1-866-223-8100
- Email: TaussigResearch@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic, Case Comprehensive Cancer Center
-
Principal Investigator:
- Stephanie Valente, DO
-
Contact:
- Stephanie A Valente, DO
- Phone Number: 866-223-8100
- Email: TaussigResearch@ccf.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects with at least 1 lesion of tumor of the breast
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Subjects who have been treated with radiation therapy on the chest.
- Has had previous sentinel lymph node biopsy
- Has a known hypersensitivity to ICG, methylene blue and 99mTc-colloid.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Integrated Imaging Goggles
Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle.
Viewed by Smart Googles and compare lesions detected by commercial FDA approved near infrared camera device (SPY Elite/Quest/PDE) in addition to those detected by gamma probe and blue dyes.
|
Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs.
The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy.
The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration).
The hand-held microscopy module has a resolution of 25 micron.
The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye.
The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off.
The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
Other Names:
Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide.
Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
Other Names:
Previously validated fluorescence detection system.
Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
Previously validated fluorescence detection system.
Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
Previously validated fluorescence detection system.
Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
Gold standard for fluorescence detection.
The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs).
The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
Gold standard for fluorescence detection.
The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs).
The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binary response of the number of participants in which the Smart Goggles identifies the same Sentinel Lymph Nodes (SLN) within each participant as those identified by the gamma probe and blue dyes gold standard.
Time Frame: At the end of the procedure, about 50 minutes
|
Agreement on 6 consecutive participants would occur less than 2% of the time by random chance (p = 0.56 = 0.016).
If the two methods agree on all 6 participants, the current protocol will end successfully.
However, if the two methods fail to agree on the SLN once among the first 6 participants, enrollment will continue to 25 participants or until a second failed agreement occurs.
|
At the end of the procedure, about 50 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binary response of the number of participants in which the Smart Goggles identifies the same Sentinel Lymph Nodes (SLN) within each participant as those identified by the SPY/Quest/PDE imaging systems.
Time Frame: At the end of the procedure, about 50 minutes
|
A commercial imaging system that measures fluorescence output of ICG will be used to measure the near infrared fluorescence in vivo.
Measurements are painless and involve no risk to the participant.
The measurements are non-contact and recorded by a computer; each measurement is painless and takes 10 seconds.
The signal is calibrated against known fluorescence standards, and the relative amount of ICG in a given measurement is interpolated from the standard curve.
|
At the end of the procedure, about 50 minutes
|
Number of samples with ICG detected in biopsy tissue
Time Frame: At the end of the procedure, about 50 minutes
|
Confirmation of ICG within lesions per histologic tissue exam by SLN biopsy.
|
At the end of the procedure, about 50 minutes
|
Number of samples with lymph node detected in biopsy tissue
Time Frame: At the end of the procedure, about 50 minutes
|
Confirmation of lymph node tissue within lesions per histologic tissue exam by SLN biopsy.
|
At the end of the procedure, about 50 minutes
|
Fluorescence intensity
Time Frame: Typically no more than 30 minutes
|
Fluorescence intensity will be compared for the removed lymph nodes between the Smart Goggles and the standard used fluorescent imaging technology. Intensity will be reported in Arbitrary units · |
Typically no more than 30 minutes
|
Number of removed lymph nodes with cancer cells
Time Frame: At the end of the procedure, about 50 minutes
|
Standard histological analyses will be performed on the biopsy specimens.
Presence of absence of cancer cells in the removed lymph nodes will serve as the source of specificity.
|
At the end of the procedure, about 50 minutes
|
Sensitivity as measured via the ICG accumulation curve
Time Frame: At the end of the procedure, about 50 minutes
|
The ICG accumulation curve generated from each device (Smart Goggles vs previously validated fluorescence imaging systems), measured on the same SLN, will be used to characterize the relative sensitivity of the Smart Goggles for ICG detection in vivo.
|
At the end of the procedure, about 50 minutes
|
Specificity as measured via the ICG accumulation curve
Time Frame: At the end of the procedure, about 50 minutes
|
The ICG accumulation curve generated from each device (Smart Goggles vs previously validated fluorescence imaging systems), measured on the same SLN, will be used to characterize the relative specificity of the Smart Goggles for ICG detection in vivo.
|
At the end of the procedure, about 50 minutes
|
Number of surgeons who prefer interventional device vs current near-infrared (NIR) cameras
Time Frame: At the end of the procedure, about 50 minutes
|
Surgeons preference for using the Googles for ICG detection versus the current near-infrared NIR cameras
|
At the end of the procedure, about 50 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephanie A Valente, DO, Cleveland Clinic, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE4116
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Cancer
-
University Health Network, TorontoCompletedBreast Cancer Invasive Nos | Primary Invasive Breast CancerCanada
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Hoffmann-La Roche; Brigham and Women's...TerminatedStage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage III Breast Cancer | Primary Invasive Breast CancerUnited States
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingBreast Cancer | Breast Cancer Non-invasive Breast CancerUnited States
-
University of California, IrvineCompletedInvasive Breast Cancer | Incident Breast Cancer
-
University Medical Center GroningenMartini Hospital GroningenRecruitingBreast Cancer | Breast Cancer InvasiveNetherlands
-
RenJi HospitalRecruitingBreast Cancer InvasiveChina
Clinical Trials on Smart Goggle
-
Vertigone Inc.Unknown
-
University of MiamiCompleted
-
Indiana UniversityWithdrawn
-
Vance Thompson VisionUnknownOcular Hypertension | Glaucoma | Glaucoma Suspect | Open Angle, Low RiskUnited States
-
Washington University School of MedicineWithdrawnHepatobiliary Surgery
-
Washington University School of MedicineTerminatedHead and Neck Cancer | Cancer of the Head and NeckUnited States
-
Chi-Ming HuangUMKC School of MedicineNot yet recruitingConcussion | Head Injury Trauma
-
Inje UniversityCompletedBRONCHIAL ASTHMAKorea, Republic of
-
St. Justine's HospitalCompletedPain | Procedural AnxietyCanada
-
Medical University of South CarolinaBoston Scientific CorporationRecruitingSubcutaneous ICD | Myopotential InterferenceUnited States